[go: up one dir, main page]

WO2009070923A1 - Composition pharmaceutique pour le traitement de la dépression et sa méthode de préparation - Google Patents

Composition pharmaceutique pour le traitement de la dépression et sa méthode de préparation Download PDF

Info

Publication number
WO2009070923A1
WO2009070923A1 PCT/CN2007/003399 CN2007003399W WO2009070923A1 WO 2009070923 A1 WO2009070923 A1 WO 2009070923A1 CN 2007003399 W CN2007003399 W CN 2007003399W WO 2009070923 A1 WO2009070923 A1 WO 2009070923A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
jujube
pharmaceutical composition
ginseng
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2007/003399
Other languages
English (en)
Chinese (zh)
Inventor
Zuoguang Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/CN2007/003399 priority Critical patent/WO2009070923A1/fr
Publication of WO2009070923A1 publication Critical patent/WO2009070923A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A61K36/725—Ziziphus, e.g. jujube
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • the present invention relates to a pharmaceutical composition for treating depression caused by ginseng and jujube, which can be used as a medicine, a nutrient and a health food.
  • the present invention also relates to a method of preparing the above pharmaceutical composition for treating depression. Background technique
  • Depression is a common disease. According to statistics, about 25% of women in the general population have experienced depression during their lifetime, and about 10% of men have experienced depression (Zhang Chunxing: Modern Psychology) . Data from the World Health Organization (WHO): The incidence of depression in the world is about 11%. There are currently about 340 million people with depression in the world, and this number is still on the rise. The survey found that in the next 20 years, depression It will rise to the second most common disease in the world.
  • WHO World Health Organization
  • the antidepressant drugs are mainly based on Prozac, Serote, Zoloft, etc. (SS-, SNRI, NDRI, etc. 5-HT, NE, DA reuptake inhibitors), and the mechanism of action is Increase the content of serotonin and other components in the human nervous medium to alleviate the symptoms of depression.
  • the anti-depressant drugs that have been asked have different degrees of side effects, such as increased suicide rate, headache, dizziness, dizziness, insomnia, lethargy, deafness, dry mouth, anorexia, increased appetite, weight gain, and increased blood pressure. , gastrointestinal discomfort, nausea, nausea, vomiting, indigestion, diarrhea, constipation, lower limb pain, skin rash, trembling, cramps, sweating, edema, loss of libido, sexual incompetence, etc.
  • anti-depressant drugs such as Prozac have become a serious concern in the society.
  • the US Food and Drug Administration (FDA) in 2004 asked the pharmaceutical companies to relabel the main 32 anti-depressants on the market.
  • FDA US Food and Drug Administration
  • the inventors have studied the pathogenesis and mechanism of action of traditional Chinese medicine for treating depression in combination with modern medical and pharmacological theories.
  • the inventors have proposed the present invention, and the object thereof is to provide A pharmaceutical composition or health food for treating depression caused by ginseng and jujube as raw materials.
  • the pharmaceutical composition is characterized by a clear functional component and a mechanism of action, and the main functional component can be quantified, so that the quality is stable, the curative effect is obvious, the safety is high, and the administration is convenient.
  • Another object of the present invention is to provide a pharmaceutical composition for the treatment of depression or a method for preparing a health food prepared by using the above-mentioned ginseng and jujube as raw materials.
  • the solution of the medicament of the invention is the result of intensive research and exploration by the inventors, according to the pathology and pharmacology theory of modern medical treatment of depression, especially the anti-depression drug target research combined with the post-receptor mechanism, after a large number of animal experiments prove: Ginsenoside contains adenylate cyclase (AC) to stimulate adenosine and contains cAMP phosphodiesterase (CAPD) inhibitor; jujube cAMP can increase the expression of cAMP in human body, and the content of jujube is extremely small.
  • AC adenylate cyclase
  • CAD cAMP phosphodiesterase
  • jujube cAMP can increase the expression of cAMP in human body, and the content of jujube is extremely small.
  • BDNF brain-derived neurotrophic factor
  • HPA axis hyperthalamic-pituitary-adrenal axis
  • glucocorticoids glucocorticoids
  • the present invention discloses a pharmaceutical composition for treating depression, which is made from a raw material including ginseng and jujube.
  • the pharmaceutical composition of the present invention is prepared from a raw material comprising 4 to 62 parts by weight of ginseng and 2 to 42 parts by weight of jujube.
  • the pharmaceutical composition of the present invention is prepared from a raw material comprising 10 to 30 parts by weight of ginseng and 4 to 20 parts by weight of jujube.
  • the present invention discloses a pharmaceutical composition for treating depression, which is prepared from a raw material including ginseng and jujube extract extract.
  • the pharmaceutical composition of the present invention comprises an extract of ginseng comprising 4 to 62 parts by weight of ginsenosides (Rgl + Rbl ) and an extract of jujube extract containing 0.01-0.2 parts by weight of jujube cyclic adenosine monophosphate. Made of raw materials.
  • the pharmaceutical composition of the present invention is a raw material comprising a ginseng extract containing 12-36 parts by weight of ginsenosides (Rgl + Rbl ) and a jujube extract containing 0.024-0.12 parts by weight of jujube cyclic adenosine monophosphate. Made.
  • the jujube extract used in the pharmaceutical composition of the present invention is the following second extract: first extracting the jujube to obtain the extract, and then purifying the first extract to obtain the second extract;
  • the concentration of the cyclic adenosine monophosphate (jujube cAMP) of the second extract in the second extract is higher than the concentration of the cyclic adenosine monophosphate of the first extract.
  • the present invention discloses a method of preparing a pharmaceutical composition for treating depression, comprising the steps of:
  • the pharmaceutical composition of the present invention can be processed into a dosage form selected from the group consisting of a tablet, a capsule, a powder, a tablet, a powder, a solution, a microclay, a suspension, an emulsion, a granule, and a drip.
  • a dosage form selected from the group consisting of a tablet, a capsule, a powder, a tablet, a powder, a solution, a microclay, a suspension, an emulsion, a granule, and a drip.
  • a dosage form selected from the group consisting of a tablet, a capsule, a powder, a tablet, a powder, a solution, a microclay, a suspension, an emulsion, a granule, and a drip.
  • the pharmaceutical compositions of the invention may comprise a pharmaceutically acceptable carrier or additive.
  • the pharmaceutical compositions of the invention are also useful in the manufacture of health foods and nutraceuticals.
  • the above pharmaceutical composition is a core formulation for achieving the object of the present invention, and after the present invention is disclosed, those skilled in the art can routinely add and subtract the above-mentioned pharmaceutical composition according to the theory of traditional Chinese medicine or related modern pharmacological theory. Such conventional addition and subtraction is a general technical activity of those skilled in the art, and any general technical additions and subtractions made on the basis of the formulation of the pharmaceutical composition of the present invention are within the scope of the present invention.
  • FIG. 1 is a schematic view showing the flow of a method for preparing a medicament of Example 1 of the present invention.
  • FIG. 2 is a schematic flow chart of a method for preparing a medicament of Example 2 of the present invention. Preferred embodiment of the invention
  • the present invention is primarily directed to the preparation of the medicaments of the present invention in combination with the features of the present invention using methods well known to those skilled in the art.
  • the following examples are for illustrative purposes only and are not intended to limit the invention.
  • the present invention particularly proposes the following technical solutions.
  • the pharmaceutical composition for treating depression of the present invention is prepared from a raw material including ginseng and jujube.
  • the pharmaceutical composition for treating depression of the present invention is prepared from a raw material comprising 4 to 62 parts by weight of ginseng and 2 to 42 parts by weight of jujube.
  • the pharmaceutical composition for treating depression of the present invention is prepared from a raw material comprising 10 to 30 parts by weight of ginseng and 4 to 20 parts by weight of jujube.
  • the pharmaceutical composition for treating depression of the present invention is prepared from a raw material comprising ginseng extract and jujube extract.
  • the medicament for treating depression of the present invention is prepared from a raw material comprising a ginseng extract containing 4-62 parts by weight of ginsenosides (Rgl + Rbl ) and a jujube extract containing 0.01-0.2 parts by weight of jujube cyclic adenosine monophosphate. combination.
  • a raw material comprising a ginseng extract containing 4-62 parts by weight of ginsenosides (Rgl + Rbl ) and a jujube extract containing 0.01-0.2 parts by weight of jujube cyclic adenosine monophosphate. combination.
  • Option six is
  • the pharmaceutical composition for treating depression is prepared from a raw material comprising a ginseng extract containing 12 36 parts by weight of ginsenosides (Rgl + Rbl ) and a jujube extract containing 0.024-0.12 parts by weight of jujube cyclic adenosine monophosphate. Things.
  • the jujube extract according to the fourth aspect of the present invention is the second extract: first extracting jujube to obtain a first extract, and then purifying the first extract to obtain a second extract; wherein the second extract
  • the concentration of the adenosine adenosine monophosphate of the substance is higher than the concentration of the adenosine adenosine monophosphate of the first extract.
  • composition of the invention for treating depression is prepared by a preparation method comprising the following steps:
  • the first extract After crushing 4-62 parts by weight of ginseng, the first extract is obtained by heating with ethanol solution or water, and the first extract is separated and purified by column chromatography to obtain a second extract, wherein The concentration of ginsenoside (Rgl + Rbl ) of the second extract is higher than the concentration of ginsenoside (Rgl + Rbl ) of the first extract
  • the pharmaceutical composition of the present invention can be processed into a dosage form selected from the group consisting of a tablet, a capsule, a powder, a tablet, a powder, a solution, a micro-dip, a suspension, an emulsion, a granule, a pill, and a pill. And one of the pharmacy oral pharmaceutical dosage forms.
  • a dosage form selected from the group consisting of a tablet, a capsule, a powder, a tablet, a powder, a solution, a micro-dip, a suspension, an emulsion, a granule, a pill, and a pill.
  • a dosage form selected from the group consisting of a tablet, a capsule, a powder, a tablet, a powder, a solution, a micro-dip, a suspension, an emulsion, a granule, a pill, and a pill.
  • compositions of the invention may include a pharmaceutically acceptable carrier or additive.
  • compositions of the invention may also be used to formulate health foods and nutrients.
  • Raw materials including ginseng and jujube are processed into a pharmaceutical composition for treating depression in the present invention.
  • a raw material comprising 4 to 62 parts by weight of ginseng and 2 to 42 parts by weight of jujube is processed to prepare a pharmaceutical composition for treating depression in the present invention.
  • a raw material comprising 10 30 parts by weight of ginseng and 4-20 parts by weight of jujube is processed to prepare a pharmaceutical composition for treating depression in the present invention.
  • a raw material including ginseng extract and jujube extract is processed to prepare a pharmaceutical composition for treating depression in the present invention.
  • ginseng extract containing 12 ⁇ 36 parts by weight of ginsenosides (Rgl + Rbl ) and
  • the raw material of the jujube extract of 0.024-0.12 parts by weight of jujube cyclic adenosine monophosphate is processed to prepare a pharmaceutical composition for treating depression in the present invention.
  • the jujube extract according to the fourth method is the following second extract: first extracting jujube to obtain a first extract, and then purifying the first extract to obtain a second extract; wherein the second extract is The concentration of cyclic adenosine monophosphate in jujube is higher than the concentration of adenosine monophosphate in the first extract.
  • composition of the invention for treating depression is prepared by a preparation method comprising the following steps:
  • Method nine The pharmaceutical composition of the present invention is processed into a dosage form selected from the group consisting of a tablet, a capsule, a powder, a tablet, a powder, a solution, an elixir, a suspension, an emulsion, a granule, a pill, and a pill. And one of the pharmacy oral pharmaceutical dosage forms.
  • compositions of the invention are processed to include a pharmaceutically acceptable carrier or additive.
  • the pharmaceutical composition of the present invention is processed into a health food and a nutrient.
  • FIG. 1 is a schematic flow chart of a method for preparing the drug of the embodiment 1 of the present invention.
  • Fig. 1 10 kg of ginseng was crushed, and the ginseng extract was extracted with 70% ethanol solution, and the ginseng extract was separated and purified by column chromatography, and dried to obtain 0.4 kg of ginseng extract (including 60).
  • FIG. 2 is a schematic flow chart of a method for preparing the drug of Example 2 of the present invention.
  • 1.2 g of ginsenoside Rgl having a purity of 90% and 2.8 g of ginsenoside Rbl having a purity of 90% are directly mixed with 0.8 g of a large amount of 0.8 mg of jujube cAMP.
  • Uniform that is, 4.8 g of the drug extract composition of the present invention.
  • mice male, weighing 22.0 ⁇ 2 g, secondary, provided by the Department of Laboratory Animal Science, Capital Medical University, Beijing.
  • Example 1 Provided by Beijing O'Neill Bioengineering Technology Co., Ltd.
  • Example 1 High dose of 60 mg/kg/d, medium dose of 30 mg/kg/d and low dose of 15 mg/kg/d
  • mice were randomized into groups of 10: 1. Example 1 high dose group (60 mg/kg, PO, 7d administration); 2. Example 1 dose group (30 mg/kg, PO, administration) 7d); 3. Example 1 low dose group (15 mg / kg, PO, 7d); 4. Paroxetine group (3 mg / kg, PO, 7d); 5. Saline group (PO) .
  • a tail suspension experiment was performed 1 hour after the last administration.
  • the tail of the mouse (1 cm from the tip of the tail) was glued to the wooden strip with a head height of 5 cm.
  • Example 1 Effect of Example 1 on immobility time in mice Number of animals in the group (only) Immobility time (seconds) Physiological benefit water group (model group) 10 122.18 ⁇ 45.78 Paroxetine group 10 67.59 ⁇ 32.09**
  • Example 1 High dose group 10 106.92 ⁇ 36.89 Example 1 medium dose group 10 59.57 ⁇ 37.63**
  • the high, medium and low dose groups and the paroxetine group of the present invention can reduce the immobility time of the mice after the tail suspension, the middle dose and the low dose group and the saline group (model group). Compared with the significant difference, it can be inferred that the first embodiment of the present invention has anti-experimental depression work.
  • ICR mice male, weighing 22.0 ⁇ 2 g, secondary, provided by the Department of Laboratory Animal Science, Capital Medical University, Beijing.
  • Example 1 Provided by Beijing O'Neill Bioengineering Technology Co., Ltd.
  • Example 1 High dose is 60 mg/kg/d, medium dose is 30 mg/kg d and low dose is I 5
  • mice were randomized into groups of 10: 1. Example 1 high dose group (60 mg/kg, PO, 7d administration); 2. Example 1 dose group (30 mg/kg, PO, administration) 7d); 3. Example 1 low dose group (15 mg / kg, PO, 7d administration); 4. Paroxetine group (3 mg kg, PO, 7d administration); 5. Saline group (PO). A forced swimming test was performed 1 hour after the last administration.
  • mice were placed in a glass jar with a water depth of 10 cm and a diameter of 14 cm, and the water temperature was 25 ° C. The cumulative immobility time of the mice in the water was recorded for 5 minutes.
  • Example 1 Low dose group 10 88.96 ⁇ 38.76 Note: Compared with the model group * P ⁇ 0.05 * ⁇ 0.01
  • the high, medium and low dose groups and the paroxetine group of the present invention can significantly shorten the cumulative immobility time of the forced swimming in the mice, the middle dose group and the high dose group and the saline group (model) There is a significant difference compared to the group), so it can be inferred that the embodiment 1 of the present invention has anti-reality Depressive depression.
  • the oral drug for treating depression according to the present invention may contain a pharmaceutically acceptable additive
  • the oral medicament for treating depression according to the present invention can be processed into various known dosage forms such as powders, capsules, tablets, and the like;
  • the oral medicament for treating depression according to the present invention can be formulated into a health food for treating depression.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composition pharmaceutique pour le traitement de la dépression et sa méthode de préparation. Cette préparation est obtenue à partir de ginseng et de jujube comme matières premières.
PCT/CN2007/003399 2007-11-30 2007-11-30 Composition pharmaceutique pour le traitement de la dépression et sa méthode de préparation Ceased WO2009070923A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2007/003399 WO2009070923A1 (fr) 2007-11-30 2007-11-30 Composition pharmaceutique pour le traitement de la dépression et sa méthode de préparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2007/003399 WO2009070923A1 (fr) 2007-11-30 2007-11-30 Composition pharmaceutique pour le traitement de la dépression et sa méthode de préparation

Publications (1)

Publication Number Publication Date
WO2009070923A1 true WO2009070923A1 (fr) 2009-06-11

Family

ID=40717256

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2007/003399 Ceased WO2009070923A1 (fr) 2007-11-30 2007-11-30 Composition pharmaceutique pour le traitement de la dépression et sa méthode de préparation

Country Status (1)

Country Link
WO (1) WO2009070923A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103704712A (zh) * 2014-01-07 2014-04-09 威海环翠楼红参科技有限公司 一种高丽红参含片的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1057380A (zh) * 1990-06-22 1992-01-01 姚育 高效滋补饮料的配方及制造工艺
CN1836687A (zh) * 2005-03-25 2006-09-27 北京欧纳尔生物工程技术有限公司 治疗抑郁症的药物组合物及其制法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1057380A (zh) * 1990-06-22 1992-01-01 姚育 高效滋补饮料的配方及制造工艺
CN1836687A (zh) * 2005-03-25 2006-09-27 北京欧纳尔生物工程技术有限公司 治疗抑郁症的药物组合物及其制法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Six Empirical Formula", THE ELDERLY, no. 1, 1999, pages 43 *
WAN SHENYAO: "Empirical Formula For Treating Hypotension", FAMILY MEDICINE, no. 1, 1995, pages 58 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103704712A (zh) * 2014-01-07 2014-04-09 威海环翠楼红参科技有限公司 一种高丽红参含片的制备方法
CN103704712B (zh) * 2014-01-07 2015-06-17 威海环翠楼红参科技有限公司 一种高丽红参含片的制备方法

Similar Documents

Publication Publication Date Title
EP2491934B1 (fr) Utilisation d'albiflorine en tant qu'antidépresseur
WO2009070915A1 (fr) Compositions pharmaceutiques destinées à traiter la dépression et l'anxiété
CN100509006C (zh) 治疗抑郁症的药物组合物及其制法
WO2009070921A1 (fr) Médicament antidépresseur à base de matériaux d'amp cylique de jujube
CN107997174B (zh) 一种具有改善睡眠和/或抗抑郁功效的保健组合物和保健食品
WO2009070924A1 (fr) Compositions pharmaceutiques avec mécanisme à rétroaction par récepteur multi-cible pour le traitement de la dépression
WO2009000145A1 (fr) Utilisation et preparation de paeoniflorine et composition associee
CN101288761B (zh) 一种治疗抑郁症的中药制剂及其制备方法
CN100379436C (zh) 一种治疗抑郁症的药物组合物及其制备方法和应用
WO2009070923A1 (fr) Composition pharmaceutique pour le traitement de la dépression et sa méthode de préparation
WO2009070922A1 (fr) Compositions pharmaceutiques pour le traitement de l'anxiété
CN101450103A (zh) 用于治疗忧郁症及焦虑症的药物组合物
TWI394576B (zh) 以人參、大棗為原料的治療憂鬱症的藥物組合物及其製法
CN101450120A (zh) 以人参、大枣为原料的治疗忧郁症的药物组合物及其制备方法
TWI400078B (zh) 以甘草、大棗為原料的治療憂鬱症的藥物組合物
CN101450121A (zh) 以甘草、大枣为原料的治疗忧郁症的药物组合物及其制法
TWI453027B (zh) 主功效成分為大棗環腺苷單磷酸之藥物作為治療憂鬱症的用途
CN101450063A (zh) 治疗忧郁症的口服药物
WO2009070916A1 (fr) Composition pharmaceutique pour le traitement de la dépression et son procédé de préparation
WO2009070917A1 (fr) Composition pharmaceutique orale pour le traitement de la barythymie
RU2456014C2 (ru) ЛЕКАРСТВЕННОЕ СРЕДСТВО ОТ МЕЛАНХОЛИИ, ПОЛУЧЕННОЕ С ИСПОЛЬЗОВАНИЕМ МАТЕРИАЛОВ С сАМР ЖУЖУБА
CN101450070A (zh) 以大枣cAMP为原料制成的抗忧郁药物
CN101450062A (zh) 多靶标受体后作用机制用于治疗忧郁症的药物组合物
TWI364287B (fr)
CN1686514A (zh) 治疗焦虑症、抑郁症的中药制剂及其生产方法

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07845762

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07845762

Country of ref document: EP

Kind code of ref document: A1